prodchem
Aug 27, 2026
India and China remain central to global pharmaceutical manufacturing, but companies increasingly want a third answer when a critical API or intermediate becomes exposed to tariffs, geopolitical disruption or concentrated supply. That search is creating new investment opportunities across Southeast Asia, South Korea, Singapore and other emerging manufacturing hubs.
The shift does not mean pharmaceutical companies are abandoning established Asian suppliers. Instead, procurement teams are building multi-origin supply chains, using new production locations to reduce dependence on any single country while preserving the cost advantages of established manufacturing centers.
For chemical traders, this creates an important change in sourcing strategy. The next generation of pharmaceutical supply contracts may involve several production countries rather than a single dominant origin.
India and China remain deeply embedded in the pharmaceutical supply chain.
China has major capabilities across APIs, intermediates and chemical starting materials. India has become a major producer of generic medicines and APIs, supported by a large pharmaceutical manufacturing ecosystem.
But concentration creates risk.
Trade restrictions, geopolitical tensions, transportation disruptions and changes in domestic industrial policy can affect procurement decisions even when suppliers continue meeting technical and quality requirements.
The response is increasingly diversification rather than replacement.
Southeast Asia stands out because pharmaceutical investment can combine expanding domestic healthcare markets with growing manufacturing capabilities.
Vietnam, Indonesia, Thailand and Singapore each offer different advantages.
Regional production is also becoming more sophisticated. Recent industry analysis identifies Southeast Asia as a long-term growth region, with foreign investment and domestic manufacturing initiatives supporting the sector.
For procurement teams, the attraction is straightforward: a second or third Asian production base can reduce dependence on China and India without requiring an immediate shift to higher-cost Western manufacturing.
Vietnam is attracting attention as pharmaceutical companies look for manufacturing locations with long-term growth potential.
The country combines a growing healthcare market with expanding local production ambitions. Pharmaceutical output is expected to rebound strongly in 2027 after a contraction in 2026, according to Atradius.
For API and intermediate sourcing, Vietnam's opportunity lies in developing deeper industrial capabilities.
The market is not yet a direct replacement for India's or China's manufacturing scale. However, companies do not necessarily need a complete replacement.
A qualified Vietnamese supplier for one critical intermediate can still materially improve supply-chain resilience.
Indonesia brings a different advantage to pharmaceutical manufacturing diversification.
Its large population supports a substantial domestic medicine market, while government policies are encouraging greater domestic production and reducing reliance on imports.
Atradius expects Indonesian pharmaceutical output to grow in both 2026 and 2027, with generic drugs driving much of the expansion.
For international manufacturers, domestic demand can help support manufacturing investments that might otherwise struggle to reach efficient scale.
That makes Indonesia particularly interesting for companies pursuing a combination of local-market production and regional supply.
Thailand already has an established pharmaceutical manufacturing base.
The country has more than 170 pharmaceutical manufacturers, with many focused on generic medicines. Industry expectations point toward greater emphasis on higher-value generics and biosimilars as regulatory standards strengthen.
That evolution matters for supply-chain diversification.
A manufacturing hub becomes more useful to global buyers when it can support increasingly complex products rather than only basic formulations.
For procurement managers, Thailand could therefore become a regional source for selected finished products, intermediates and specialized pharmaceutical manufacturing services.
Singapore has one of the region's most established biopharmaceutical manufacturing ecosystems.
The country hosts more than 60 biomedical manufacturing plants, including facilities operated by eight of the world's top 10 biopharmaceutical companies. In 2025, Singapore's Economic Development Board attracted S$4.4 billion in biomedical-sector investments, including a US$1.5 billion antibody-drug conjugate facility announced by AstraZeneca.
Singapore's value proposition is therefore based less on low-cost manufacturing and more on advanced production, infrastructure, regulatory capabilities and proximity to Asian markets.
The country already produces small-molecule APIs, biologics and newer modalities including ADCs
South Korea is another important diversification destination, particularly for high-value pharmaceutical manufacturing.
The country's capabilities increasingly extend into biologics, ADCs, oligonucleotides and other technically complex modalities.
Recent industry coverage identifies South Korea and Singapore as key APAC locations expanding capabilities across advanced pharmaceutical technologies.
That makes South Korea especially relevant to companies that are not simply looking for a low-cost API source.
For advanced medicines, manufacturing quality, technical expertise and process capabilities can matter more than labor costs.
Australia and Japan represent another layer of diversification.
Neither country is likely to replace China as a broad-based source of pharmaceutical intermediates.
Their strategic value lies in specialized manufacturing.
Recent APAC industry analysis highlights new viral-vector and cell-therapy investments in Australia and Japan, broadening the region's advanced-therapy manufacturing infrastructure.
For procurement teams, these markets can provide additional options for specialized products where technical capability and supply security justify higher production costs.
There is an important twist in the diversification story.
Companies reducing dependence on China may increase their dependence on India.
India itself is investing heavily in domestic KSM, drug-intermediate and API capacity. Government data show that 38 projects covering 28 critical products had been commissioned by December 2025, creating approximately 56,800 tonnes per year of manufacturing capacity.
India's Production Linked Incentive program also supports domestic manufacturing of critical pharmaceutical inputs.
This strengthens India's position as an alternative source, but it does not eliminate concentration risk if global buyers simply replace one dominant origin with another.
The strongest diversification strategy does not ask, "Which country replaces China?"
It asks, "How many viable sources do we need for this material?"
A procurement team could source:
A primary API from India.
A qualified backup from South Korea.
A critical intermediate from Vietnam.
Specialized processing from Singapore.
Selected raw materials from established Chinese suppliers.
The exact combination depends on the product.
This model creates redundancy without forcing companies to abandon competitive suppliers.
Diversification has a cost.
Qualifying another pharmaceutical supplier requires technical assessment, audits, documentation and potentially regulatory work.
Companies should therefore focus first on materials where concentration creates genuine business risk.
Priority candidates include:
Single-source APIs.
Critical KSMs.
Long-lead-time intermediates.
Materials with limited global production.
Products exposed to tariff changes.
Inputs with a history of supply disruption.
Materials requiring lengthy regulatory qualification.
A widely available solvent does not necessarily require the same diversification strategy as a critical API.
As buyers add new origins, supplier qualification becomes more important.
A low-cost supplier is not useful if it cannot meet pharmaceutical specifications consistently.
Procurement teams should evaluate new manufacturing hubs using a common framework.
Key criteria include:
Regulatory capability: Can the supplier meet the required pharmaceutical quality standards?
Manufacturing scale: Can production support commercial volumes?
Supply reliability: Does the plant have dependable utilities, labor and logistics?
Upstream security: Where do its starting materials come from?
Export infrastructure: Can products reach major pharmaceutical markets efficiently?
Expansion capacity: Can the supplier increase output as demand grows?
This helps buyers distinguish genuine diversification from simply moving one dependency to another.
A pharmaceutical company may source an API from Vietnam and assume it has reduced Chinese exposure.
That conclusion could be wrong.
If the Vietnamese manufacturer imports its critical intermediate from China, the supply chain remains indirectly dependent on Chinese production.
The same issue can apply to Indian suppliers.
India has strengthened domestic production of critical KSMs and APIs, but government and industry sources continue to recognize dependence on imported raw materials and intermediates, particularly from China.
Procurement teams therefore need tier-two and tier-three visibility.
A new manufacturing origin only improves resilience if the logistics network can support it.
Buyers should examine port infrastructure, shipping frequency, air-freight availability, customs procedures and transit times.
This is particularly important for temperature-sensitive or high-value pharmaceutical materials.
Singapore has an advantage in this area because of its established infrastructure and proximity to major Asian markets.
Other emerging hubs may offer lower manufacturing costs but require more careful logistics planning.
Pharmaceutical companies cannot diversify without considering economics.
India and China achieved their positions partly because of manufacturing scale, established supplier networks and cost competitiveness.
Emerging hubs must therefore provide enough value to justify qualification and potentially higher production costs.
The winning locations will likely combine several factors:
competitive manufacturing + regulatory reliability + infrastructure + skilled labor + geopolitical stability
No single factor is enough.
The next wave of diversification will not necessarily focus only on conventional APIs.
Companies are also investing in high-value modalities.
Recent APAC investment activity includes specialized manufacturing for HPAPIs, ADCs, oligonucleotides, mRNA, biologics, cell therapies and sterile products.
That creates opportunities for countries that can build technical capabilities quickly.
For procurement teams, this means future supplier maps should include manufacturing technology, not simply geographic origin.
The most interesting development may be the emergence of Southeast Asia as a connected pharmaceutical manufacturing region.
Singapore can provide advanced manufacturing and regional coordination.
Thailand has an established generic manufacturing base.
Vietnam is expanding pharmaceutical production.
Indonesia combines domestic demand with manufacturing development.
These markets do not need to compete individually with India or China.
Together, they can provide a broader diversification platform.
The diversification trend should not be mistaken for an end to China's pharmaceutical importance.
China has enormous chemical manufacturing capacity and extensive integration across upstream raw materials, intermediates and APIs.
Replacing that ecosystem completely would be expensive and time-consuming.
That is why most pharmaceutical companies are likely to pursue a China-plus-one or China-plus-multiple strategy rather than a complete withdrawal.
The objective is resilience, not geographic purity.
India also remains central to global pharmaceutical sourcing.
Its large formulation industry, expanding API capacity and deep regulatory experience make it difficult to replace.
Current Indian policy is actively supporting domestic production of critical APIs, KSMs and drug intermediates, reinforcing the country's role in global pharmaceutical supply chains.
The more realistic scenario is therefore a broader supplier portfolio in which India remains one of several strategic origins.
Pharmaceutical buyers can turn diversification into a structured sourcing program.
Start with the highest-risk materials and build outward.
First, map concentration. Identify APIs and intermediates where one country supplies most or all qualified capacity.
Second, identify realistic alternatives. Look at Vietnam, Thailand, Indonesia, Singapore, South Korea, Japan and Australia according to the technical requirements of each product.
Third, investigate upstream exposure. Determine whether a proposed alternative supplier still depends on India or China for critical inputs.
Fourth, qualify before the crisis. A backup supplier has little value if regulatory qualification takes longer than the expected disruption.
Fifth, negotiate strategically. Capacity reservations and long-term agreements can make alternative sources commercially viable before buyers actually need them.
The diversification cycle creates several opportunities for chemical trading businesses.
Watch for new API plants, KSM investments and pharmaceutical industrial parks in emerging hubs.
Also monitor companies expanding into advanced modalities, because those facilities can generate demand for specialized intermediates, solvents, reagents and other pharmaceutical-grade chemicals.
The most valuable market signal may not be a new finished-drug plant.
It may be a new upstream chemical facility that enables an entire cluster of pharmaceutical manufacturers.
The evidence points toward a distributed Asian manufacturing landscape rather than one new dominant hub.
Southeast Asia offers growth and geographic diversification. Singapore and South Korea offer advanced capabilities. Japan and Australia can support specialized manufacturing. India continues expanding domestic API and KSM production.
At the same time, the United States and Europe are investing in domestic resilience for strategically important products.
The result could be a pharmaceutical supply chain with several regional centers instead of the highly concentrated structure that defined earlier globalization.
Pharmaceutical supply-chain diversification is moving beyond the simple idea of replacing one country with another. India and China will remain fundamental suppliers, but buyers increasingly need qualified alternatives that can reduce concentration risk across APIs, KSMs and intermediates.
Southeast Asia offers some of the most interesting opportunities, with Vietnam, Indonesia and Thailand developing manufacturing capabilities while Singapore continues attracting sophisticated biopharmaceutical investment. South Korea, Japan and Australia add specialized capabilities that are particularly relevant to biologics, ADCs, advanced therapies and high-value pharmaceutical production.
For procurement teams, the winning strategy is not to chase the newest manufacturing hub. It is to build a portfolio of qualified origins based on product criticality, regulatory requirements, upstream dependencies, logistics and total landed cost.
Featured Product
Found this useful?
Continue Reading
Henkel's 2026 acquisition of Stahl Holdings highlights a broader shift toward consolidation and vertical integration in advanced materials. DuPont's Qnity restructuring and Merck's Taiwan investment show how suppliers are repositioning around electronics growth.
The US and India are investing in domestic semiconductor ecosystems, including specialty gases and process chemicals. New projects signal a global shift toward localized chip supply chains.
Advanced 2.5D packaging is creating major new demand for specialty chemicals as chiplets, silicon interposers and dense interconnects require etching, copper filling, CMP and lithography.
